SCIENCE · VERIFIED DEVELOPMENT
Flu Season Nears: New mRNA Vaccine Adds to Options as Cases Rise
WHY IT MATTERS
Early flu vaccination protects vulnerable populations and reduces hospitalizations, especially as new mRNA technology expands vaccine choices and the season may begin sooner than usual.
What happened
Health officials warn that the 2026‑27 U. S. flu season may start early in some western states as respiratory infections rise.
The CDC recommends vaccination for everyone 6 months and older, with enhanced shots for adults 65 and older. In August 2026 the FDA approved mFLUSIVA, the first mRNA‑based influenza vaccine, available to adults 50 and older, though many sites may still lack it. Other options include FluMist nasal spray for ages 2‑49, Flucelvax made in mammalian cells, and higher‑dose or lab‑grown vaccines for seniors.
Vaccination remains the strongest protection, especially for high‑risk groups such as the elderly, young children, pregnant people, and those with chronic conditions. Updated COVID‑19 shots can be given at the same visit.
PRIMARY SOURCES
Flu season is near – here’s a guide to available vaccines
The Conversation US · Annette Regan, Adjunct Associate Professor of Epidemiology, University of California, Los Angeles · CC BY-ND; link/attribution intake only—no edited republication
CORRECTIONS & UPDATES
- Revision 1 · Initial ingestion · Oct 6, 2026, 10:30 PM
- Revision 2 · Source update detected · Oct 6, 2026, 10:30 PM